ΕΡΕΥΝΑ ΚΑΙ ΔΗΜΟΣΙΕΥΣΕΙΣ
Κλινικές Μελέτες
Συμμετοχή
σε περισσότερες από 40 κλινικές μελέτες
Δημοσιεύσεις
1. Konstantinopoulos PA, Fountzilas E, Pillay K, et al. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC medical genomics 2008;1:59.
2. Burga LN, Tung NM, Troyan SL, et al. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer research 2009;69:1273-8.
3. Konstantinopoulos PA, Fountzilas E, Goldsmith JD, et al. Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PloS one 2010;5:e9747.
4. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28:3555-61.
5. Konstantinopoulos PA, Spentzos D, Fountzilas E, et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer research 2011;71:5081-9.
6. Konstantinopoulos PA, Cannistra SA, Fountzilas H, et al. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PloS one 2011;6:e18202.
7. Fountzilas E, Kelly AD, Perez-Atayde AR, et al. A microRNA activity map of human mesenchymal tumors: connections to oncogenic pathways; an integrative transcriptomic study. BMC genomics 2012;13:332.
8. Pentheroudakis G, Nicolaou I, Kotoula V, et al. Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx. Oral oncology 2012;48:709-16.
9. Fountzilas E, Markou K, Vlachtsis K, et al. Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2012;23:2146-53.
10. Pectasides D, Papaxoinis G, Kotoula V, et al. Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study. Oncology reports 2012;27:216-24.
11. Mountzios G, Kostopoulos I, Kotoula V, et al. Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PloS one 2013;8:e54048.
12. Dionysopoulos D, Pavlakis K, Kotoula V, et al. Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2013;189:202-14.
13. Fountzilas E, Kotoula V, Angouridakis N, et al. Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer. PloS one 2013;8:e70429.
14. Pentheroudakis G, Kotoula V, Fountzilas E, et al. A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). BMC cancer 2014;14:111.
15. Krikelis D, Kotoula V, Bobos M, et al. Protein and mRNA expression of notch pathway components in operable tumors of patients with laryngeal cancer. Anticancer research 2014;34:6495-503.
16. Koumarianou A, Tzeveleki I, Mekras D, et al. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. Anticancer research 2014;34:4949-62.
17. Psyrri A, Kotoula V, Fountzilas E, et al. Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer. Oral oncology 2014;50:298-305.
18. Fountzilas E, Kotoula V, Zagouri F, et al. Disease evolution and heterogeneity in bilateral breast cancer. American journal of cancer research 2016;6:2611-30.
19. Fountzilas E, Krishnan E, Janku F, et al. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer chemotherapy and pharmacology 2018;82:877-85.
20. Fountzilas E, Levva S, Mountzios G, et al. Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities. Journal of global oncology 2018;4:1-12.
21. Fountzilas E, Kotoula V, Tikas I, et al. Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. Oncotarget 2018;9:35623-38.
22. Fountzilas E, Palmer G, Vining D, Tsimberidou AM. Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma. JCO precision oncology 2018;2.
23. Fountzilas E, Said R, Tsimberidou AM. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert opinion on investigational drugs 2018;27:155-62.
24. Fountzilas E, Tsimberidou AM. Overview of precision oncology trials: challenges and opportunities. Expert review of clinical pharmacology 2018;11:797-804.
25. Kotoula V, Fostira F, Fountzilas E. Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer-Beyond the Misdiagnosis. JAMA oncology 2019;5:740-1.
26. Fountzilas E, Kotoula V, Pentheroudakis G, et al. Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. ESMO open 2019;4:e000474.
27. Tsimberidou AM, Fountzilas E, Bleris L, Kurzrock R. Transcriptomics and solid tumors: The next frontier in precision cancer medicine. Seminars in cancer biology 2020.
28. Fountzilas E, Koliou GA, Vozikis A, et al. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. ESMO open 2020;5.
29. Fountzilas E, Kotoula V, Koliou GA, et al. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget 2020;11:1-14.
30. Kust D, Murgic J, Vukovic P, et al. Oncologist Burnout Syndrome in Eastern Europe: Results of the Multinational Survey. JCO oncology practice 2020;16:e366-e76.
31. Fountzilas E, Konstantopoulou I, Vagena A, et al. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Clinical breast cancer 2020;20:152-9.
32. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer treatment reviews 2020;86:102019.
33. Fountzilas E, Ignatiadis M. Neoadjuvant immunotherapy in breast cancer: a paradigm shift? Accepted at ecancermedicalscience 2020.
34. Fountzilas E, Eliades A, Koliou GA, et al: Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. Cancers (Basel) 13, 2021
35. Kotoula V, Papadopoulou K, Tikas I et al. Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries. Breast Cancer 2021.
36. Fountzilas E, Kurzrock R, Hiep Vo H, Tsimberidou AM. Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. J Natl Cancer Inst 2021.
37. Apostolou P, Dellatola V, Papadimitriou C et al. CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects. Cancers (Basel) 2021; 13.
38. Fountzilas E, Kotoula V, Koliou GA et al. Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough? Front Oncol 2021; 11: 683057.
39. Fountzilas E, Lampaki S, Koliou GA et al. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. Cancer Immunol Immunother 2021.
40. Kotoula V, Papadopoulou K, Tikas I, et al. Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries. Breast cancer (Tokyo, Japan) 2021.
41. Linardou H, Spanakis N, Koliou GA, et al. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. Cancers 2021;13.
42. Mountzios G, Samantas E, Senghas K, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO open 2021;6:100254.
43. Fountzilas E, Apostolou P, Vasiliadis AV et al. Physicians' experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece. Fam Cancer. 2022 Jan 24.
44. Fostira F, Fountzilas E, Papadopoulou K et al. Lung cancer as a predominant feature in a patient with Peutz-Jeghers syndrome: case report. Thorac Cancer. 2022 Jun;13(12):1862-1865
45. Nikolaidi A, Fountzilas E, Fostira F et al. Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges. Front Oncol. 2022 Jul 26;12:820128
Commentary
- Fountzilas E, Pentheroudakis G. The role of Sym004, a novel EGFR antibody mixture, in patients with refractory colorectal cancer, Translational Cancer Research, Vol 5, Supplement 1 (2016).
- Kotoula V, Fostira F, Fountzilas E. Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer-Beyond the Misdiagnosis. JAMA Oncol. 2019 Apr 11
.svg){kind=small}
.svg){kind=small}
